Navigation Links
Oncolytics Biotech Inc. Announces Issuance of 28th U.S. Patent
Date:9/30/2008

CALGARY, Sept. 30 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") today announced that it has been granted U.S. Patent 7,429,485 entitled "Method of Producing Infectious Reovirus". The claims cover methods of purifying reassorted reovirus from an FDA-approved cell line.

"This patent provides broad protection for methods of producing reassorted reovirus," said Mary Ann Dillahunty, Vice President of Intellectual Property for Oncolytics. "It expands our already substantial portfolio of patents which cover the production of therapeutic reovirus."

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

This news release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including among others, the Company's belief as to the importance of the issuance of this patent, the safety and efficacy of the reovirus, the Company's expectations as to the potential applications of the patented technology and other statements relating to anticipated developments in the Company's business and technologies, involve known and unknown risks and uncertainties that could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, uncertainties rela
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... This webinar will focus on EMA ... assessment in biosimilars. , Regulatory frameworks are evolving many ... however the complex nature of biopharmaceuticals makes the demonstration ... extremely challenging. Based on the specific aspects of biosimilar ...
(Date:1/15/2014)... Houston, TX (PRWEB) January 15, 2014 ... Alzheimer’s disease, and about 1 in 3 seniors will ... ( source ). These jaw-dropping figures have shocked many ... function and, hopefully, help prevent these tragic age-related cognitive ...
(Date:1/15/2014)... NY (PRWEB) January 15, 2014 The Microcompetition ... a major disease. One of these latent viruses is the ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic inflammatory ... theory, a study found that RA patients have high concentrations ...
(Date:1/15/2014)... 2013 was a banner year of continued ... saw continued independent research led by the team at ... $1 million grant from the Susanne Marcus Collins Foundation, ... peer reviewed journal, Amy Grant highlighted Brainwave Optimization® in ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3
... Reportlinker.com announces that a new market research report is ... - technologies, markets and companies ... Up-to-date on-stop information on gene therapy with 72 tables and ... - 700 selected references from the literature ...
... announces that a new market research report is ... applications, markets and companies ... creation and utilization of materials, devices, and systems ... scale (a nanometer is one billionth of a ...
... strip with two surfaces but only one side, has been ... German mathematician August Mbius. As artist M.C. Escher so vividly ... traverse the "inside" and "outside" surfaces of a Mbius strip ... searching for an example of Mbius symmetry in natural materials ...
Cached Biology Technology:Reportlinker Adds Gene Therapy - technologies, markets and companies 2Reportlinker Adds Gene Therapy - technologies, markets and companies 3Reportlinker Adds Gene Therapy - technologies, markets and companies 4Reportlinker Adds Gene Therapy - technologies, markets and companies 5Reportlinker Adds Gene Therapy - technologies, markets and companies 6Reportlinker Adds Gene Therapy - technologies, markets and companies 7Reportlinker Adds Gene Therapy - technologies, markets and companies 8Reportlinker Adds Gene Therapy - technologies, markets and companies 9Reportlinker Adds Gene Therapy - technologies, markets and companies 10Reportlinker Adds Gene Therapy - technologies, markets and companies 11Reportlinker Adds Gene Therapy - technologies, markets and companies 12Reportlinker Adds Gene Therapy - technologies, markets and companies 13Reportlinker Adds Gene Therapy - technologies, markets and companies 14Reportlinker Adds Gene Therapy - technologies, markets and companies 15Reportlinker Adds Gene Therapy - technologies, markets and companies 16Reportlinker Adds Gene Therapy - technologies, markets and companies 17Reportlinker Adds Gene Therapy - technologies, markets and companies 18Reportlinker Adds Gene Therapy - technologies, markets and companies 19Reportlinker Adds Gene Therapy - technologies, markets and companies 20Reportlinker Adds Gene Therapy - technologies, markets and companies 21Reportlinker Adds Nanobiotechnologies- applications, markets and companies 2Reportlinker Adds Nanobiotechnologies- applications, markets and companies 3Reportlinker Adds Nanobiotechnologies- applications, markets and companies 4Reportlinker Adds Nanobiotechnologies- applications, markets and companies 5Reportlinker Adds Nanobiotechnologies- applications, markets and companies 6Reportlinker Adds Nanobiotechnologies- applications, markets and companies 7Reportlinker Adds Nanobiotechnologies- applications, markets and companies 8Reportlinker Adds Nanobiotechnologies- applications, markets and companies 9Reportlinker Adds Nanobiotechnologies- applications, markets and companies 10Reportlinker Adds Nanobiotechnologies- applications, markets and companies 11Reportlinker Adds Nanobiotechnologies- applications, markets and companies 12Reportlinker Adds Nanobiotechnologies- applications, markets and companies 13Reportlinker Adds Nanobiotechnologies- applications, markets and companies 14Reportlinker Adds Nanobiotechnologies- applications, markets and companies 15Reportlinker Adds Nanobiotechnologies- applications, markets and companies 16
(Date:7/9/2014)... of increasing concern about the prevalence of antibiotic-resistant ... promising new pathway to disabling disease: blocking bacteria,s ... scientists showed how bacterial siderophore, a small molecule, ... fan bacterial growth as well as how ... infection process. Their findings appear in a recent ...
(Date:7/9/2014)... season upon us, many backyard cooks are turning to ... dogs. But low fat can sometimes mean low satisfaction. ... texture problem in low-fat wieners that are made with ... published in ACS, Journal of Agricultural and Food ... that hot-dog consumers have come to expect just the ...
(Date:7/9/2014)... re-examination of a sparrow-sized fossil from China challenges the ... dinosaurs that gained the ability to fly. The birdlike ... but much rather the remains of a tiny tree-climbing ... of the Dinosaur Museum in Blanding, Utah, and Alan ... appears in Springer,s Journal of Ornithology . , ...
Breaking Biology News(10 mins):Bacteria hijack plentiful iron supply source to flourish 2Researchers declassify dinosaurs as being the great-great-grandparents of birds 2
... always been what they are today, particularly for omnivores. ... tigers and other big cats as examples. Other mammals ... on a diet of leaves, shoots, fruits and bark. ... addition to meat, the situation wasn,t always that way, finds ...
... , This release is available in ... the US and Europe harbour more plant species than ... closer related to each other and often share similar ... environmental impacts than rural ecosystems. This is concluded by ...
... 18/04/12 - Technology has transformed the way humans interact with ... ideas that will drive growth in marine and maritime sectors ... policy will gather at the 3rd Marine Board Forum in ... Board has convened this flagship event on the understanding that ...
Cached Biology News:Scientists trace evolutionary history of what mammals eat 2Live fast, die young 2New technologies for a blue future 2
Eagle's Ham's amino acids; EHAA...
... IRsolution software provides quick and easy operation ... with Windows-based control. The software is ... FDA 21 CFR Part 11 regulations, and ... measurement. IRsolutions versatility enables use in ...
... introduce random mutations to the gene supplied by ... into a vector of choice to obtain a ... can be set to a desired value within ... 106-108. Mutations can be restricted to a ...
... EVOlyzer is Tecans new Enzyme-Linked Immunosorbent Assay ... Freedom EVOlyzer is a dedicated EVO platform ... reader, washer and incubation units operated by ... EVOlyzer is available in three sizes - ...
Biology Products: